New York, Jan 13, 2026, 18:27 EST — After-hours
- J&J shares climbed roughly 1.9% during regular hours and held steady after the bell.
- Delaware’s highest court has called for a redo of the $1 billion damages tally linked to Auris.
- Investors are turning their attention to the results coming out on Jan. 21 and new pipeline updates from healthcare conferences.
Johnson & Johnson shares climbed about 1.9%, closing at $213.65 on Tuesday, and stayed near that level in after-hours trading after Delaware’s highest court pared down part of a $1 billion damages award related to its Auris Health acquisition. The Delaware Supreme Court ordered a recalculation that could shave a few hundred million dollars, including interest, off the total. This dispute traces back to J&J’s 2019 purchase of surgical-robot maker Auris and the earnout payments tied to performance milestones owed to former shareholders. “We are pleased that the court reversed the trial court’s improper substitution,” J&J said. Reuters
Why it matters now: legal news rarely moves the needle for a company this large on a daily basis, but the Auris ruling throws a fresh number—or at least a narrower range—into play. That’s significant as healthcare investor meetings ramp up and earnings season kicks off, where guidance usually sets the tone.
At Monday’s J.P. Morgan Healthcare Conference, CEO Joaquin Duato sounded upbeat about 2026. “We see the company doing better in 2026 than in 2025,” he said, pointing to “visibility for double-digit growth” later this decade, per a session transcript. Seeking Alpha
J&J also highlighted upcoming neuroscience and psychiatry data scheduled for release this week, focusing on depression treatments. The company noted that the presentations will cover new insights into anhedonia — the challenging symptom marked by an inability to feel pleasure.
The broader market worked against J&J. U.S. stocks closed a bit lower following an inflation report, as investors continued to digest its implications for interest rate moves.
Big pharma showed a mixed picture today: AbbVie managed a slight uptick, but Pfizer dipped, which made J&J’s rally stand out even more.
The Auris battle isn’t settled yet. With the final bill still up in the air, a rougher quarter in medical devices or a surprise legal hit could swiftly shift the outlook.
Johnson & Johnson will release its fourth-quarter 2025 earnings and hold a call on Jan. 21 at 8:30 a.m. ET. Investors will focus on the company’s outlook, any insights from recent conferences, and whether management sees the recent court ruling as an isolated incident or a broader warning about deal-related liabilities.
